Background and Purpose: Stroke is one of the leading causes of mortality and long-term disability. Prompt diagnosis and treatment of stroke are crucial for a better outcome. A blood test, which serves as a biomarker in rural areas will help in immediately transferring patients to a hospital for thrombolytic therapy. The aim of the present study was to examine the role of ischemia modified albumin (IMA) as a screening biomarker in acute ischaemic stroke. Materials and Methods: Serum samples were collected from 50 patients with acute ischaemic stroke within one, 24, 48, 72 and 144 h of time of admission for IMA. We compared patients’ 1st-hour value with age- and sex-matched controls by independent sample t test. p value < 0.05 was considered significant. Results: The serum IMA levels of patients 1st hour (108 ± 8.9) were significantly higher than those of the controls (79 ± 6.3) p < 0.05. The IMA levels showed a steady decline at 1 h (108 ± 8.9), 24 h (94 ± 4.2), 48 h (82 ± 6.1), 72 h (77 ± 5.6) and 144 h (76 ± 3.8) of admission in patients. Conclusion: We observed that serum IMA was significantly higher in stroke patients as compared to controls. IMA was elevated in the acute phase of stroke and had a gradual graded decline over 1 week. We concluded that IMA may be a sensitive and rapid biomarker for screening of early ischaemic stroke in rural settings.

Keywords:
Stroke, Biomarker, Ischemia modified albumin
1.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al: Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 119: 489–486.
2.
Kim MH, Kang SY, Kim MC, Lee WI: Plasma biomarkers in the diagnosis of acute ischemic stroke. Ann Clin Lab Sci 2010; 40: 336–341.
3.
Cuzzocrea S, Riley DP, Caputi AP, Salvemini D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001; 53: 135–159.
4.
Bar-Or D, Lau E, Winkler JV: A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000; 19: 311–315.
5.
Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC: Role of IMA, a new biochemical marker of myocardial ischeamia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29–34.
6.
Nayak AR, Kashyap RS, Kabra D, Purohit HJ, Taori GM, Daginawala HF: Prognostic significance of ischemia-modified albumin in acute ischemic stroke patients: a preliminary study. Ann Neurosci 2011; 18: 5–7.
7.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of -cerebral infarction. Lancet 1991; 337: 1521–1526.
8.
National Institute of Health, National Institute of Neurological Disorders and Stroke. Stroke Scale. http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.
9.
Chan B, Dodsworth N, Woodrow J, Tucker A, Harris R: Site-specific N-terminal auto-degradation of human serum albumin. Eur J Biochem 1995; 227: 524–528.
10.
Hlatky MA: Exercise testing to predict outcome in patients with angina. J Gen Intern Med 1999; 14: 63–65.
11.
Gunduz A, Turedi S, Mentese A, et al: Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008; 26: 874–878.
12.
McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159–163.
13.
Gutierrez-Correa J, Stoppani AO: Inactivation of yeast glutathione reductase by Fenton systems: effect of metal chelators, catecholamines and thiol compounds. Free Radic Res 1997; 27: 543–555.
14.
Lippi G, Montagnana M: Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg 2009; 15: 137.
15.
Senes M, Kazan N, Coskun O, Zengi O, Inan L, Yücel D: Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007; 44: 43–47.
16.
Can M, Demirtas S, Polat O, Yildiz A: Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma. Emerg Med J 2006; 23: 537–539.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.